Vobarilizumab
Based on 1 Customer Validation
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 1628814-88-9
- Molecular Weight:25.69 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
VH-VH'
Human
IL-6Ra & ALB
Vobarilizumab shows a preferential binding affinity for sIL-6R compared with mIL-6R[2].
Vobarilizumab (0-10 nM) blocks the interaction of recombinant hIL-6 to recombinant hsIL-6R[3].
Vobarilizumab (0-100 nM) blocks proliferation of the TF-1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vobarilizumab (0.4-10 mg/kg, i.v.) shows a prolonged exposure through binding to serum albumin in cynomolgus monkeys[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:hIL-6-induced inflammation in cynomolgus monkey[3]
-
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Pharmacokinetic parameters of Vobarilizumab
dose (mg/kg) T1/2 dominant (day) AUCinf (μg/day/mL) CL (mL/day/kg) Vss (mL/kg) 0.4 (i.v.) 1.73 16.3 24.8 42.8 2 (i.v.) 5.0 193 10.4 53.7 10 (i.v.) 6.61 1136 9 82.7
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH'
ELISA, FACS, Functional assay
-
Immobilized Human IL-6R Protein (ECD, His Tag) can bind Vobarilizumab. The EC50 for this effect is 2.34 ng/mL. -
Immobilized Serum Albumin/ALB Protein, Human (HEK293, His-Avi, HY-P78393) can bind Vobarilizumab. The EC50 for this effect is 183.3 ng/mL.
Chemical Information
-
CAS No. 1628814-88-9
-
Appearance Liquid
-
Molecular Weight 25.69 kDa
-
Color Colorless to light yellow
-
SMILES
[Vobarilizumab]
-
Synonyms
ALX-0061
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759. [Content Brief]
[3]. Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vobarilizumab Related Classifications
HY-P99385 Related Classifications
Powered by Bioz